t
ValiRx PLC announced on 20 November 2025 that all resolutions at its General Meeting were passed, and it applied for 256,067,800 new shares to be admitted to AIM on 21 November 2025. The company also issued 368,372,400 Fundraising Warrants exercisable at 0.5 pence and 16,036,120 Broker Warrants. Directors Mark Eccleston, Cathy Tralau-Stewart, Gerry Desler, and Martin Gouldstone collectively purchased 39,600,000 new ordinary shares at 0.25 pence each on 20 November 2025, leading to a total issued share capital of 742,721,072 ordinary shares post-admission.
| Date | 20 Nov 2025 |
| Time | 12:11:58 |
| Category | AGMs and other meetings |
| ID | 3996I |
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
20 November 2025
VALIRX PLC
("ValiRx" or the "Company")
Result of General Meeting
Issue of Equity and Total Voting Rights
Director and PDMR Shareholding
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, further to the announcement on 4 November 2025, at the Company's General Meeting held earlier today, all resolutions were duly passed. Details of the votes received in respect of the resolutions will be available shortly on the Company's website.
Issue of Equity
The Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares have been allotted, conditional upon Admission, and application has been made to the London Stock Exchange for, in aggregate, 256,067,800 Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on 21 November 2025, with dealings in the Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares commencing at the same time. The Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares will rank pari passu with all other issued Shares.
Issue of Warrants
Pursuant to the Fundraising and in connection with the issuance of the Fee Shares the Company has issued 368,372,400 Fundraising Warrants. The Fundraising Warrants will be exercisable at a price of 0.5 pence per Ordinary Share and are exercisable at any time until the third anniversary of Tranche 2 Admission.
In addition, the Company has issued 16,036,120 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of Tranche 2 Admission.
Director and PDMR Shareholdings
Following completion of the Fundraising, the shareholdings of the Directors who participated in the Fundraising are set out in the table below:
|
Name |
Number of existing Ordinary Shares |
Percentage of existing issued share capital |
Number of New Ordinary Shares |
Number of Ordinary Shares on Tranche 2 Admission |
Percentage of enlarged share capital on Tranche 2 Admission |
|
Mark Eccleston |
22,746,187 |
6.08% |
36,000,000 |
58,746,187 |
7.91% |
|
Cathy Tralau-Stewart |
835,897 |
0.22% |
1,200,000 |
2,035,897 |
0.27% |
|
Gerry Desler |
964,565 |
0.26% |
1,200,000 |
2,164,565 |
0.29% |
|
Martin Gouldstone |
769,231 |
0.21% |
1,200,000 |
1,969,231 |
0.27% |
|
Total |
25,315,880 |
6.76% |
39,600,000 |
64,915,880 |
8.74% |
|
|
|
|
|
|
|
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 742,721,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the Circular dated 4 November 2025, unless otherwise defined in this announcement.
The Directors of the Company take responsibility for this announcement.
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
https://valirx.com/link/yEMZvy |
|
ValiRx plc
Dr Mark Eccleston, CEO |
Tel: +44 115 784 0026 |
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Broker) Damon Heath Andrew Gutmann |
Tel: +44 (0) 20 7186 9000 |
|
SP Angel Corporate Finance LLP (Placing Agent) David Hignell Vadim Alexandre |
Tel: +44 (0) 20 3470 0470 |
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director |
+44 (0) 115 787 0206 |
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a. |
Name |
A) Mark Eccleston B) Cathy Tralau-Stewart C) Gerry Desler D) Martin Gouldstone |
||||||
|
2 |
Reason for notification |
|
||||||
|
a. |
Position/Status |
A) Director B) Director C) Director D) Director |
||||||
|
b. |
Initial notification/ Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
ValiRx PLC |
||||||
|
b. |
LEI |
213800VQKB9SJCQDET40 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary Shares
ISIN: GB00BLH13C52 |
||||||
|
b. |
Nature of the transaction |
Purchase of shares as part of the Fundraising |
||||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
||
|
|
Price(s) |
Volume(s) |
|
|||||
|
A) 0.25 pence |
36,000,000 |
|
||||||
|
|
B) 0.25 pence |
1,200,000 |
|
|||||
|
|
C) 0.25 pence |
1,200,000 |
|
|||||
|
|
D) 0.25 pence |
1,200,000 |
|
|||||
|
|
||||||||
|
d. |
Aggregated information - Aggregated Volume - Price |
N/A
|
||||||
|
e. |
Date of the transaction |
20 November 2025 |
||||||
|
f. |
Place of the transaction |
Outside a trading venue
|
||||||
|
|
|
|
|
|
|
|
|
|
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a. |
Name |
A) Mark Eccleston B) Cathy Tralau-Stewart C) Gerry Desler D) Martin Gouldstone |
||||||
|
2 |
Reason for notification |
|
||||||
|
a. |
Position/Status |
A) Director B) Director C) Director D) Director |
||||||
|
b. |
Initial notification/ Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
ValiRx PLC |
||||||
|
b. |
LEI |
213800VQKB9SJCQDET40 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the financial instrument, type of instrument |
Warrants over new Ordinary Shares exercisable at a price of 0.5 pence per share
ISIN: GB00BLH13C52 |
||||||
|
b. |
Nature of the transaction |
Warrants as part of the Fundraising |
||||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
||
|
|
Price(s) |
Volume(s) |
|
|||||
|
A) 0.5 pence |
36,000,000 |
|
||||||
|
|
B) 0.5 pence |
1,200,000 |
|
|||||
|
|
C) 0.5 pence |
1,200,000 |
|
|||||
|
|
D) 0.5 pence |
1,200,000 |
|
|||||
|
|
||||||||
|
d. |
Aggregated information - Aggregated Volume - Price |
N/A
|
||||||
|
e. |
Date of the transaction |
20 November 2025 |
||||||
|
f. |
Place of the transaction |
Outside a trading venue
|
||||||
|
|
|
|
|
|
|
|
|
|
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving and reading this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.